Malignant neoplasm of breast
|
0.600 |
Biomarker
|
disease |
BEFREE |
Androgen treatment inhibits ER signaling in ER+/AR+ breast cancer cell lines, and AR expression is associated with improved survival for this subtype in epidemiologic studies.
|
30795773 |
2019 |
Malignant neoplasm of breast
|
0.600 |
AlteredExpression
|
disease |
BEFREE |
In the prospective Nurses' Health Study cohort, we evaluated alcohol consumption and breast cancer risk by individual tumor marker expression (i.e., ER, progesterone receptor [PR], AR, and IR) while controlling for other markers and also assessed the joint effect of these receptors.
|
26385458 |
2015 |
Malignant neoplasm of breast
|
0.600 |
AlteredExpression
|
disease |
BEFREE |
Lack of both androgen receptor and forkhead box A1 (FOXA1) expression is a poor prognostic factor in estrogen receptor-positive breast cancers.
|
29137314 |
2017 |
Malignant neoplasm of breast
|
0.600 |
Biomarker
|
disease |
BEFREE |
Divergent roles for androgen receptor (AR) in breast cancer have been reported.
|
31289138 |
2019 |
Malignant neoplasm of breast
|
0.600 |
AlteredExpression
|
disease |
BEFREE |
Furthermore, the level of AR staining in PC-3AR+ cells was higher than in the androgen-responsive breast cancer cell lines ZR-75-1, T47-D, and MCF-7.
|
7792809 |
1995 |
Malignant neoplasm of breast
|
0.600 |
AlteredExpression
|
disease |
BEFREE |
Decreased androgen receptor levels and receptor function in breast cancer contribute to the failure of response to medroxyprogesterone acetate.
|
16166329 |
2005 |
Malignant neoplasm of breast
|
0.600 |
Biomarker
|
disease |
BEFREE |
The significance of androgen receptor (AR) in breast cancer (BC) management is not fully defined, and it is still ambiguous how the level of AR expression influences oestrogen receptor-positive (ER+) tumours.
|
29386247 |
2018 |
Malignant neoplasm of breast
|
0.600 |
GeneticVariation
|
disease |
BEFREE |
Among postmenopausal Caucasian women, common variants of the AR gene are not associated with risk of breast cancer.
|
16987421 |
2006 |
Malignant neoplasm of breast
|
0.600 |
AlteredExpression
|
disease |
BEFREE |
Treatment of MDA-MB-453 with CREBBP/EP300 bromodomain inhibitors downregulates the expression of an AR-dependent signature distinctive of breast cancer tumors that express AR and causes a decrease in H3K27ac levels at AR-binding sites.
|
30606771 |
2019 |
Malignant neoplasm of breast
|
0.600 |
AlteredExpression
|
disease |
BEFREE |
Androgen receptor levels and association with PIK3CA mutations and prognosis in breast cancer.
|
19276248 |
2009 |
Malignant neoplasm of breast
|
0.600 |
AlteredExpression
|
disease |
BEFREE |
Molecular apocrine (MA) tumors are estrogen receptor (ER) negative breast cancers characterized by androgen receptor (AR) expression.
|
23663520 |
2013 |
Malignant neoplasm of breast
|
0.600 |
Biomarker
|
disease |
BEFREE |
Other steroid hormone receptors such as progesterone receptor (PR) and androgen receptor (AR) are emerging as additional prospective targets in breast cancer.
|
27796944 |
2017 |
Malignant neoplasm of breast
|
0.600 |
GeneticVariation
|
disease |
BEFREE |
In summary, we observed no overall relation of AR genotype with breast cancer risk among mostly postmenopausal Caucasian women.
|
11861380 |
2002 |
Malignant neoplasm of breast
|
0.600 |
GeneticVariation
|
disease |
BEFREE |
However, larger scale primary study is required to further evaluate the interaction of AR CAG polymorphism and breast cancer risk.
|
20431938 |
2010 |
Malignant neoplasm of breast
|
0.600 |
Biomarker
|
disease |
BEFREE |
<b>Purpose:</b> Steroidal androgens suppress androgen receptor and estrogen receptor positive (AR/ER<sup>+</sup>) breast cancer cells and were used to treat breast cancer, eliciting favorable response.
|
28974548 |
2017 |
Malignant neoplasm of breast
|
0.600 |
Biomarker
|
disease |
BEFREE |
Phase Ib patients (ER+ or TNBC) with AR+ breast cancer received 160 mg enzalutamide in combination with taselisib to determine dose-limiting toxicities and the maximum tolerated dose (MTD).
|
31822498 |
2019 |
Malignant neoplasm of breast
|
0.600 |
Biomarker
|
disease |
BEFREE |
A new progesterone receptor-negative, androgen receptor-positive human breast cancer cell line, designated Y-AR, was engineered and characterized.
|
16457685 |
2005 |
Malignant neoplasm of breast
|
0.600 |
Biomarker
|
disease |
BEFREE |
Recently, F7 gene has been identified as a direct target of the androgen receptor in breast cancer.
|
27434295 |
2016 |
Malignant neoplasm of breast
|
0.600 |
Biomarker
|
disease |
BEFREE |
Unlike canonical AR signaling which is inhibited by enzalutamide, non-canonical AR activity is not effectively antagonized by enzalutamide, and this has important implications in the design of future AR-targeted clinical trials in endocrine-resistant breast cancer.
|
30557851 |
2019 |
Malignant neoplasm of breast
|
0.600 |
Biomarker
|
disease |
BEFREE |
The present data indicate that androgens can down-regulate bcl-2 protooncogene levels via an androgen receptor-mediated mechanism, thus providing a novel mechanism for their known inhibitory effect on breast cancer cell growth.
|
9886853 |
1999 |
Malignant neoplasm of breast
|
0.600 |
Biomarker
|
disease |
BEFREE |
This case report supports the literature regarding the possible association between Leydig cell tumor and androgen-receptor-positive breast cancer development.
|
28443693 |
2017 |
Malignant neoplasm of breast
|
0.600 |
Biomarker
|
disease |
BEFREE |
Our findings delineate a mechanism of cancer stem cell regulation by the DYRK2-AR-KLF4 axis in breast cancer.
|
27721402 |
2017 |
Malignant neoplasm of breast
|
0.600 |
Biomarker
|
disease |
BEFREE |
Androgens and AR have been reported to facilitate tumor stemness in some cancers; a process which may be mediated through genomic or non-genomic actions of the AR, with the latter mechanism being relatively unexplored in breast cancer.
|
30416486 |
2018 |
Malignant neoplasm of breast
|
0.600 |
Biomarker
|
disease |
BEFREE |
These data represent the rationale for AR-targeting treatment as a potentially new target therapy in breast cancer subset using androgen agonists in some AR-positive/ER-positive tumors, AR antagonists in triple-negative/AR-positive tumors and in combination with anti-HER2 agents or with other signaling pathways inhibitors (including PI3K/MYC/ERK) in HER2-positive/AR-positive tumors.
|
27528625 |
2016 |
Malignant neoplasm of breast
|
0.600 |
Biomarker
|
disease |
BEFREE |
Furthermore, expression of estrogen receptor (ER) is a high relevant molecular event with key therapeutic implications in breast cancer, and androgen receptor (AR) signaling is involved in the pathogenesis of breast cancer and represents a novel target with crescent importance in this disease.
|
28916342 |
2017 |